

Infectious Disease Blueprint

Certification Examination (CERT)

Purpose of the exam

The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified infectious disease specialist in the broad domain of the discipline. The ability to make appropriate diagnostic and management decisions that have important consequences for patients will be assessed. The exam may require recognition of common as well as rare clinical problems for which patients may consult a certified infectious disease specialist.

Exam content

Exam content is determined by a pre-established blueprint, or table of specifications. The blueprint is developed by ABIM and is reviewed annually and updated as needed for currency. Trainees, training program directors, and certified practitioners in the discipline are surveyed periodically to provide feedback and inform the blueprinting process.

The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:

Medical Content Category	% of Exam
Bacterial Diseases	27%
Human Immunodeficiency Virus (HIV) Infection	15%
Antimicrobial Therapy	9%
Viral Diseases	7%
Travel and Tropical Medicine	5%
Fungi	5%
Immunocompromised Host (Non-HIV Infection)	5%
Vaccinations	4%
Infection Prevention and Control	5%
Internal Medicine and Non-Infectious Syndromes	18%
	100%

ABIM is committed to working toward health equity and believes that board-certified physicians should have an understanding of health care disparities. Therefore, health equity content that is clinically important to each discipline will be included in assessments, and the use of gender, race, and ethnicity identifiers will be re-evaluated.

Exam format

The exam is composed of up to 240 single-best-answer multiple-choice questions, of which approximately 40 are new questions that do not count in the examinee's score. Most questions describe patient scenarios and ask about the work done (that is, tasks performed) by physicians in the course of practice:

- Making a diagnosis
- Ordering and interpreting results of tests
- Recommending treatment or other patient care
- Assessing risk, determining prognosis, and applying principles from epidemiologic studies
- Understanding the underlying pathophysiology of disease and basic science knowledge applicable to patient care

Clinical information presented may include patient photographs, radiographs, electrocardiograms, recordings of heart or lung sounds, and other media to illustrate relevant patient findings. Learn more information on how exams are developed.

A tutorial including examples of ABIM exam question format can be found at http://www.abim.org/certification/exam-information/infectious-disease/exam-tutorial.aspx.

The blueprint can be expanded for additional detail as shown below. Each of the medical content categories is listed there, and below each major category are the content subsections and specific topics that *may* appear in the exam. The inherent complexity of the field of infectious disease leads to considerable overlap in content categories, and each question can only be assigned to a single blueprint topic. Thus, a question addressing the cause of fever and rash likely would be classified under the specific organism, while a similar question addressing the treatment of that same illness would be classified under the antimicrobial agent used. Please note: actual exam content may vary.



Bacterial Diseases 27% of Exam

Gram-positive cocci

Staphylococcus aureus

Streptococcus

Enterococcus

Gram-positive rods

Listeria

Corynebacterium

Bacillus

Erysipelothrix

Gram-negative cocci and coccobacilli

Neisseria

Haemophilus

Gram-negative rods

Enterobacteriaceae

Pseudomonas

Stenotrophomonas

Burkholderia

Acinetobacter

Aeromonas

Salmonella

Shigella

Campylobacter

Vibrio

Pasteurella

Yersinia

Legionella

Capnocytophaga

Bartonella

Brucella

Bordetella

Streptobacillus

Francisella

Helicobacter

Anaerobes

Gram-positive cocci

Gram-positive rods

Gram-negative rods



Actinomycetes

Actinomyces

Nocardia

Spirochetes

Treponema

Borrelia

Leptospira

Mycoplasma

M. pneumoniae

M. genitalium

Tropheryma whipplei

Chlamydia

C. trachomatis

C. pneumoniae

C. psittaci

Rickettsia

R. conorii

R. akari

R. rickettsii

R. prowazekii

R. typhi

Orientia tsutsugamushi

R. parkeri

R. africae

Coxiella burnetii

Ehrlichia

E. chaffeensis

E. ewingii

Anaplasma phagocytophilum

Mycobacterium

M. tuberculosis

M. bovis

M. leprae

Nontuberculous mycobacteria

Syndromes characterized by bacterial pathogens

Head and neck

Respiratory

Gastrointestinal

Ophthalmologic



Genitourinary

Dermatologic (including skin and soft-tissue infections)

Musculoskeletal

Neurologic

Cardiovascular

Human Immunodeficiency Virus (HIV) Infection

15% of Exam

Epidemiology

Transmission

Testing and counseling

Initial laboratory evaluation

Prevention

Pathogenesis

Virology

Immunopathogenesis

Acute HIV infection

Laboratory testing

Diagnostic evaluation

Baseline evaluation

HIV treatment regimens

Antiretroviral therapy drug classes

Adverse effects of treatment

Drug-drug interactions

When to start therapy

Selection of optimal initial regimen

Laboratory monitoring

Treatment-experienced patients

Opportunistic infections (OIs)

Prevention

When to start HIV therapy in the context of active OIs

Immune reconstitution inflammatory syndrome

Bacteria

Mycobacteria

Fungi

Parasites

Viruses

Malignancies

Kaposi sarcoma

Lymphoma



Cervical cancer

Anal cancer

Other complications of HIV

Hematologic

Endocrine

Gastrointestinal

Renal (HIV-associated nephropathy [HIVAN])

Cardiac (HIV cardiomyopathy)

Pulmonary

Head, eye, ear, nose, and throat

Musculoskeletal

Neurologic

Psychiatric

Dermatologic

Related issues

Substance use

Organ transplantation

Primary care

Miscellaneous non-HIV-related complications that may occur

more commonly in those who have HIV

Pregnancy

Antimicrobial Therapy

9% of Exam

Antibacterials

Aminoglycosides

Antifolates

Carbapenems

Cephalosporins

Fluoroquinolones

Glycopeptides, glycolipopeptides, and lipopeptides

Lincosamides

Macrolides

Monobactams

Nitroimidazoles

Oxazolidinones

Penicillins

Polymyxins

Rifamycins



Tetracyclines

Non-sulfonamide (sulfa drug), non-trimethoprim

urinary tract agents

Pleuromutilins (e.g., lefamulin)

Topical antibacterials

Other routes of administration

Antivirals (non-HIV)

For influenza

For herpes simplex

For cytomegalovirus

For hepatitis C and respiratory syncytial virus (RSV)

For hepatitis B

Interferon alfa 2a and alfa 2b

For hepatitis C

Pharmacology and outpatient parenteral antimicrobial

therapy (OPAT)

Susceptibility testing

Drug resistance

ADME (absorption, distribution, metabolism, and excretion)

Dosing

Drug interactions

Toxicity

Outpatient parenteral antimicrobial therapy

Viral Diseases 7% of Exam

DNA viruses

Herpesviruses

Adenovirus

Papillomavirus

Polyomavirus

Poxviruses

Hepadnaviridae

Parvovirus

RNA viruses

Reoviridae (e.g., rotavirus)

Togaviridae (e.g., chikungunya)

Flaviviridae

Coronaviridae



Paramyxoviridae

Rhabdoviridae

Filoviridae (hemorrhagic fever viruses)

Orthomyxoviridae (influenza)

Bunyaviridae (e.g., Rift Valley fever, Crimean-Congo hemorrhagic fever,

Sin Nombre virus)

Arenaviridae (e.g., lymphocytic choriomeningitis virus)

Non-HIV retroviridae

Picornaviridae

Calciviridae

Hepatitis E

Prions

Travel and Tropical Medicine

5% of Exam

Protozoal intestinal infections

Balantidium coli

Blastocystis hominis

Cryptosporidium parvum and C. hominis

Cyclospora cayetanensis

Cystoisospora (Isospora) belli

Dientamoeba fragilis

Entamoeba histolytica (amebiasis)

Giardiasis

Microsporidiosis

Protozoal extraintestinal infections

Amebic meningoencephalitis

Babesiosis

Leishmaniasis

Malaria

Toxoplasmosis

Trichomonas vaginalis

Trypanosomiasis (general)

Nematode intestinal infections

Anisakiasis

Ascaris lumbricoides (ascariasis)

Capillaria philippinesis (capillariasis)

Enterobius vermicularis (pinworm)

Hookworm



Strongyloides stercoralis

Trichuris trichiura (whipworm)

Nematode extraintestinal infections

Angiostrongylus cantonensis

Bayliascariasis (raccoon roundworm)

Cutaneous larva migrans (dog and cat hookworm)

Dracunculus medinensis (Guinea worm)

Filariasis

Gnathostoma spinigerum

Toxocariasis

Trichinella spiralis (trichinellosis)

Cestode infections

Diphyllobothrium latum (fish tapeworm)

Hymenolepis (dwarf tapeworm)

Echinococcus granulosus (hydatid disease)

Echinococcus multilocularis (alveolar disease)

Taenia saginata (beef tapeworm)

Taenia solium (pork tapeworm; intestinal)

Trematode infections (flukes)

Clonorchis sinensis (Chinese liver fluke)

Fasciolopsis buski (intestinal fluke)

Fasciola hepatica and gigantica (sheep liver fluke)

Paragonimus westermani (lung fluke)

Schistosomiasis (general)

Ectoparasitic infections

Myiasis (human botfly or tumbu fly)

Pediculus humanus (body, head, and pubic lice)

Tick bites—identification and tick paralysis

Tungiasis (*Tunga penetrans*)

Bed bugs

General principles of travel medicine

Pretravel preparation

Post-travel Illness

Immigrants, refugees, and adoptees

Travelers with specific needs



Fungi 5% of Exam

Yeasts

Candida

Cryptococcus

Other yeasts (including *Trichosporon* and *Saccharomyces*)

Endemic mycoses

Histoplasma

Blastomyces dermatitidis

Coccidioides immitis (C. posadasii)

Sporothrix schenckii

Paracoccidioides brasiliensis

Talaromyces (Penicillium) marneffei

Molds

Aspergillus

Hyaline molds

Agents of zygomycosis (mucormycosis)

Dematiaceous molds (Bipolaris, Exophila, and others)

Superficial and subcutaneous mycoses

Mycetoma

Chromoblastomycosis

Malassezia

Dermatophytes

Pneumocystis jirovecii pneumonia (PJP)

Therapy

Agents

Pharmacokinetics

Drug interactions

Spectrum

Toxicity

Prophylaxis

Susceptibility testing

Drug resistance

Diagnostic testing

Histopathology

Culture

Nonculture methods



Syndromes

Mucosal

Skin

Pulmonary

Central nervous system and eyes

Cardiac

Disseminated

Immunocompromised Host (Non-HIV Infection)

5% of Exam

Primary immunodeficiency

Anatomic lesions

Lymphocyte defects

Combined immunodeficiency syndromes (including severe

combined immunodeficiency [SCID])

Phagocytes

Complement deficiencies

NK cell deficiencies

Hematologic malignancies and stem cell transplantation

Infections associated with chemotherapy-induced neutropenia

Stem cell transplant

Syndromes

Noninfectious conditions

Solid-organ transplantation

Donor-derived infections

Surgical site infections

Hospital-acquired infection

Opportunistic infections

Noninfectious conditions

Complications of immunosuppression in non-transplant population

(disease-modifying agents, including tumor necrosis

factor [TNF] blockers, corticosteroids)

Bacteria

Fungi

Viruses

Parasites and protozoa

Infection prevention in the immunosuppressed host

Immunizations

Antimicrobials

Environmental control



Vaccinations 4% of Exam

Active immunizations (vaccines)

Pneumococcal

Influenza

Tetanus, diphtheria, and acellular pertussis

Haemophilus influenzae

Hepatitis B

Hepatitis A

Measles, mumps, and rubella

Polio

Meningococcal

Rabies

Varicella

Herpes zoster

Human papillomavirus (HPV)

Passive immunizations

Varicella-zoster virus

Rabies

Hepatitis B

Tetanus

Immune globulin

Other (including cytomegalovirus immune globulin)

Infection Prevention and Control

5% of Exam

Applied epidemiology and biostatistics

Outbreak investigation

Healthcare quality improvement

Healthcare-associated infections (HAIs) of organ systems

HAIs related to intravascular devices,

short-term and long-term (including contaminated infusions)

HA urinary tract infections and pneumonia infections

HA surgical site infections

HAIs of other organ systems (including gastrointestinal

tract infections, and central nervous system infections)

Epidemiology and prevention of HAIs caused by specific pathogens

Bacterial infections

Mycobacterial and fungal infections

Viral infections



Epidemiology and prevention of HAIs in special patient populations

HAIs in obstetrics

HAIs in neoplastic diseases

HAIs in organ transplant and hematopoietic stem cell transplant

Epidemiology and prevention of HAIs in therapeutic procedures

Infection risks of endoscopy

HAIs associated with hemodialysis and peritoneal dialysis

HAIs related to other procedures (including cardiology and respiratory therapy)

HAIs following transfusion of blood and blood products

Fecal transplantation

Prevention of HAIs related to hospital support services

Environmental services

Disinfection and sterilization

Epidemiology and prevention of HAIs in healthcare workers

Prevention of occupationally acquired viral hepatitis in

healthcare workers

Prevention of occupationally acquired HIV infection in

healthcare workers

Vaccination of healthcare workers

Prevention of occupationally acquired diseases of healthcare

workers spread by contact, droplet, or airborne precautions

(other than TB, and including diagnostic laboratories)

Organization and implementation of infection control programs

Surveillance of HAIs

Isolation precautions

Hand antisepsis

Epidemiology and prevention of infections in residents of

long-term care facilities

Infection control in countries with limited resources

Internal Medicine and Non-Infectious Syndromes

18% of Exam

General internal medicine

Malignancies

Hemophagocytic lymphohistiocytosis (Hemophagocytic syndrome)

Noninfectious inflammatory disorders (e.g., vasculitis,

lupus, inflammatory bowel disease)

Dermatologic disorders



Hematologic disorders

Noninfectious central nervous system disease

Bites, stings, and toxins

Drug fever

Ethical and legal decision making

Surgical infections

Orthopedic

Neurosurgery

Ear, nose, and throat

General surgery and intra-abdominal

Thoracic and cardiothoracic

Urologic

Obstetric and gynecologic

Plastic and reconstructive

Vascular

Critical care medicine

Systemic inflammatory response syndrome (SIRS) and sepsis

Ventilator-associated pneumonias

Noninfectious pneumonias (eosinophilic and acute

respiratory distress syndrome [ARDS])

Bacterial pneumonias

Viral pneumonias

Hyperthermia and hypothermia

E-cigarette or vaping product use—associated lung injury (EVALI)

January 2025

